IN2012DN00412A - - Google Patents
Download PDFInfo
- Publication number
- IN2012DN00412A IN2012DN00412A IN412DEN2012A IN2012DN00412A IN 2012DN00412 A IN2012DN00412 A IN 2012DN00412A IN 412DEN2012 A IN412DEN2012 A IN 412DEN2012A IN 2012DN00412 A IN2012DN00412 A IN 2012DN00412A
- Authority
- IN
- India
- Prior art keywords
- fibrosis
- tgfbetarii
- lopm
- skin
- suitably
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Abstract
ABSTRACT ANTI-TGF-BETA RECEPTOR TYPE I1 SINGLE DOMAIN ANTIBODIES The invention provides an anti-TGFbetaRII immunoglobulin single variable domain. Suitably, an anti-TGFbetaRII immunoglobulin single variable domain in accordance with the invention is one which binds to TGFbetaRII with a dissociation constant (Kd) in the range of lOpM to 50nM, preferably lOpM to lOnM, preferably 250pM to 10nM. Isolated polypeptides comprising an amino acid sequence that is at least 70% identical to at least one amino acid sequence selected from the group of: SEQ ID NOS: 1 to 23, wherein said isolated polypeptide binds to TGFbetaRII are also provided. The invention also provides a polypeptide, ligand or pharmaceutical composition for treating a disease associated with TGFbeta signalling and suitably a disease selected from the group of: tissue fibrosis, such as pulmonary fibrosis, including idiopathic pulmonary fibrosis, liver fibrosis, including cirrhosis and chronic hepatitis, rheumatoid arthritis, ocular disorders, or fibrosis of the skin, including keloid of skin, and kidney such as nephritis, kidney fibrosis and nephrosclerosis, and a vascular condition, such as restenosis.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US22933409P | 2009-07-29 | 2009-07-29 | |
PCT/EP2010/060867 WO2011012609A2 (en) | 2009-07-29 | 2010-07-27 | Ligands that bind tgf-beta receptor rii |
Publications (1)
Publication Number | Publication Date |
---|---|
IN2012DN00412A true IN2012DN00412A (en) | 2015-05-22 |
Family
ID=43067099
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IN412DEN2012 IN2012DN00412A (en) | 2009-07-29 | 2010-07-27 |
Country Status (15)
Country | Link |
---|---|
US (1) | US9109031B2 (en) |
EP (1) | EP2459593A2 (en) |
JP (2) | JP2013500030A (en) |
KR (1) | KR20120063475A (en) |
CN (1) | CN102574922A (en) |
AU (1) | AU2010277629B2 (en) |
BR (1) | BR112012001977A2 (en) |
CA (1) | CA2768981A1 (en) |
EA (1) | EA026097B1 (en) |
IL (1) | IL217458A0 (en) |
IN (1) | IN2012DN00412A (en) |
MX (1) | MX2012001278A (en) |
SG (1) | SG178135A1 (en) |
WO (1) | WO2011012609A2 (en) |
ZA (1) | ZA201200372B (en) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9150651B2 (en) | 2011-01-06 | 2015-10-06 | Glaxo Group Limited | Single variable domain immunoglobulins that bind TGF-beta receptor II |
US20190119387A1 (en) * | 2016-04-05 | 2019-04-25 | Glaxosmithkline Intellectual Property Development Limited | Inhibition of tgfbeta in immunotherapy |
GB201608052D0 (en) * | 2016-05-09 | 2016-06-22 | Univ Oslo Hf | T-cell receptors which recognise frameshift mutants of TGF-beta RII |
WO2018057522A1 (en) * | 2016-09-20 | 2018-03-29 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Harnessing protein-based drugs comprising an anchor domain for use on the ocular surface |
JP2020526218A (en) | 2017-07-14 | 2020-08-31 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | A new way to predict the risk of transplant rejection |
JP2021516966A (en) | 2018-03-09 | 2021-07-15 | ユニバーシティ オブ ピッツバーグ − オブ ザ コモンウェルス システム オブ ハイヤー エデュケイション | Delivery of biological drugs to tissues |
GB201807693D0 (en) * | 2018-05-11 | 2018-06-27 | Autolus Ltd | Cell |
EP4291227A2 (en) | 2021-02-15 | 2023-12-20 | Takeda Pharmaceutical Company Limited | Cell therapy compositions and methods for modulating tgf-b signaling |
Family Cites Families (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1994026087A2 (en) | 1993-05-14 | 1994-11-24 | Connor Kim C O | Recombinant protein production and insect cell culture and process |
IL127127A0 (en) | 1998-11-18 | 1999-09-22 | Peptor Ltd | Small functional units of antibody heavy chain variable regions |
JP2001206899A (en) * | 1999-11-18 | 2001-07-31 | Japan Tobacco Inc | HUMAN MONOCLONAL ANTIBODY AGAINST TGF-beta II TYPE RECEPTOR AND MEDICINAL USE THEREOF |
US20050053973A1 (en) | 2001-04-26 | 2005-03-10 | Avidia Research Institute | Novel proteins with targeted binding |
US20050089932A1 (en) | 2001-04-26 | 2005-04-28 | Avidia Research Institute | Novel proteins with targeted binding |
JP4303105B2 (en) | 2001-06-28 | 2009-07-29 | ドマンティス リミテッド | Dual specific ligands and their use |
US20030028905A1 (en) * | 2001-07-31 | 2003-02-06 | Petra Knaus | Mutant forms of the TGF-beta type II receptor which bind all TGF-beta isoforms |
US20080108560A1 (en) | 2002-03-05 | 2008-05-08 | Eli Lilly And Company | Heterologous G-Csf Fusion Proteins |
DK1517921T3 (en) | 2002-06-28 | 2006-10-09 | Domantis Ltd | Immunoglobulin single variable antigen binding domains and double specific constructs thereof |
US7696320B2 (en) | 2004-08-24 | 2010-04-13 | Domantis Limited | Ligands that have binding specificity for VEGF and/or EGFR and methods of use therefor |
US20060002935A1 (en) | 2002-06-28 | 2006-01-05 | Domantis Limited | Tumor Necrosis Factor Receptor 1 antagonists and methods of use therefor |
US9321832B2 (en) | 2002-06-28 | 2016-04-26 | Domantis Limited | Ligand |
JP2004121001A (en) * | 2002-08-07 | 2004-04-22 | Japan Tobacco Inc | HIGH-AFFINITY MONOCLONAL ANTIBODY TO TRANSFORMING GROWTH FACTOR-betaTYPE II RECEPTOR |
EP2316852B1 (en) | 2002-11-08 | 2014-03-05 | Ablynx N.V. | Stabilized single domain antibodies |
CA2511910A1 (en) | 2002-12-27 | 2004-07-15 | Domantis Limited | Dual specific single domain antibodies specific for a ligand and for the receptor of the ligand |
WO2004101790A1 (en) | 2003-05-14 | 2004-11-25 | Domantis Limited | A process for recovering polypeptides that unfold reversibly from a polypeptide repertoire |
AU2004220325B2 (en) | 2003-06-30 | 2011-05-12 | Domantis Limited | Polypeptides |
WO2005040229A2 (en) | 2003-10-24 | 2005-05-06 | Avidia, Inc. | Ldl receptor class a and egf domain monomers and multimers |
CN102816241B (en) | 2004-02-09 | 2015-07-22 | 人类基因科学公司 | Albumin fusion proteins |
DE602005023291D1 (en) | 2004-03-24 | 2010-10-14 | Domantis Ltd | UNIVERSAL SIGNAL PEPTIDE GAS1 |
US7563443B2 (en) * | 2004-09-17 | 2009-07-21 | Domantis Limited | Monovalent anti-CD40L antibody polypeptides and compositions thereof |
KR20080098382A (en) | 2006-01-24 | 2008-11-07 | 도만티스 리미티드 | Ligands that bind il-4 and/or il-13 |
GB0724331D0 (en) | 2007-12-13 | 2008-01-23 | Domantis Ltd | Compositions for pulmonary delivery |
-
2010
- 2010-07-27 CN CN2010800450323A patent/CN102574922A/en active Pending
- 2010-07-27 US US13/387,376 patent/US9109031B2/en not_active Expired - Fee Related
- 2010-07-27 IN IN412DEN2012 patent/IN2012DN00412A/en unknown
- 2010-07-27 JP JP2012522147A patent/JP2013500030A/en active Pending
- 2010-07-27 SG SG2012006029A patent/SG178135A1/en unknown
- 2010-07-27 KR KR1020127005555A patent/KR20120063475A/en not_active Application Discontinuation
- 2010-07-27 EA EA201290028A patent/EA026097B1/en not_active IP Right Cessation
- 2010-07-27 AU AU2010277629A patent/AU2010277629B2/en not_active Ceased
- 2010-07-27 WO PCT/EP2010/060867 patent/WO2011012609A2/en active Application Filing
- 2010-07-27 EP EP10735014A patent/EP2459593A2/en not_active Withdrawn
- 2010-07-27 BR BR112012001977A patent/BR112012001977A2/en not_active Application Discontinuation
- 2010-07-27 CA CA2768981A patent/CA2768981A1/en not_active Abandoned
- 2010-07-27 MX MX2012001278A patent/MX2012001278A/en not_active Application Discontinuation
-
2012
- 2012-01-10 IL IL217458A patent/IL217458A0/en unknown
- 2012-01-17 ZA ZA2012/00372A patent/ZA201200372B/en unknown
-
2015
- 2015-10-09 JP JP2015201067A patent/JP2016053039A/en active Pending
Also Published As
Publication number | Publication date |
---|---|
MX2012001278A (en) | 2012-03-16 |
AU2010277629B2 (en) | 2016-05-19 |
SG178135A1 (en) | 2012-03-29 |
BR112012001977A2 (en) | 2017-01-31 |
WO2011012609A2 (en) | 2011-02-03 |
IL217458A0 (en) | 2012-02-29 |
KR20120063475A (en) | 2012-06-15 |
ZA201200372B (en) | 2013-06-26 |
US9109031B2 (en) | 2015-08-18 |
JP2016053039A (en) | 2016-04-14 |
EA201290028A1 (en) | 2012-08-30 |
AU2010277629A1 (en) | 2012-02-16 |
EP2459593A2 (en) | 2012-06-06 |
CN102574922A (en) | 2012-07-11 |
EA026097B1 (en) | 2017-03-31 |
CA2768981A1 (en) | 2011-02-03 |
WO2011012609A3 (en) | 2011-09-15 |
US20120129778A1 (en) | 2012-05-24 |
JP2013500030A (en) | 2013-01-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IN2012DN00412A (en) | ||
JP7007333B2 (en) | Peptides with anti-inflammatory activity and compositions containing them | |
JP6788062B2 (en) | Peptides with anti-inflammatory activity and compositions containing them | |
MX2013007936A (en) | Ligands that bind tgf-beta receptor ii. | |
WO2013184960A3 (en) | Chimeric fibroblast growth factor 23 proteins and methods of use | |
AU2015202477B2 (en) | Antibodies that bind csf1r | |
HRP20151227T1 (en) | Compositions and methods of use for therapeutic antibodies | |
EA201201047A1 (en) | METHODS AND COMPOSITIONS IN WHICH APPLY FGF 23 POLYPEPTIDES | |
Hovanessian | Midkine, a cytokine that inhibits HIV infection by binding to the cell surface expressed nucleolin | |
EA201100546A1 (en) | POLYPEPTIDES, VARIABLE DOMAINS OF ANTIBODIES AND ANTAGONISTS | |
JP6797810B2 (en) | Anti-CD40L Antibodies and Methods for Treating CD40L-Related Diseases or Disorders | |
HRP20220811T1 (en) | Agonistic tnf receptor binding agents | |
MX2021001424A (en) | Methods and compositions for treatment of angiogenic disordres using anti-vegf agents. | |
SI3134430T1 (en) | Single-chain trail-receptor agonist proteins | |
EP3345925A3 (en) | Humanized antibodies targeting the ec1 domain of cadherin-11 and related compositions and methods | |
KR20120137270A (en) | A fusion protein for inhibiting both angiogenesis and tumor cell proliferation, and composition comprising the same | |
RU2678810C2 (en) | CHIMERIC PROTEIN COMPOSED OF NGF ANTAGONIST DOMAIN AND TNFα ANTAGONIST DOMAIN | |
JP2024001292A (en) | MULTI-SPECIFIC Wnt SURROGATE MOLECULES AND USES THEREOF | |
MA29339B1 (en) | FUSED THIAZOLE DERIVATIVES WITH AFFINITY FOR HISTAMINE H3 RECEPTOR | |
RU2011110459A (en) | RECOMBINANTLY OBTAINED HUMAN FACTOR VIII AND IX | |
Song et al. | Arginines in the CDR of anti‐dsDNA autoantibodies facilitate cell internalization via electrostatic interactions | |
NZ599114A (en) | Stable anti-tnfr1 polypeptides, antibody variable domains & antagonists | |
MX2016011852A (en) | Compositions and methods for preventing or treating chronic lung allograft dysfunction and idiopathic pulmonary fibrosis. | |
WO2008060814A3 (en) | ANTI-IL-13Rα1 ANTIBODIES AND THEIR USES THEREOF | |
EP2344175B1 (en) | Methods for suppressing toll-like receptor activity |